Literature DB >> 22918770

Rare metastases detected by (68)Ga-somatostatin receptor PET/CT in patients with neuroendocrine tumors.

Cecilia Carreras1, Harshad R Kulkarni, Richard P Baum.   

Abstract

AIM: The most common sites of metastasis in neuroendocrine tumors are liver, lymph nodes, and bone. The aim of this study is to determine the prevalence and location of other sites of metastasis.
METHODS: 4,210 Ga-68 somatostatin-receptor PET/CT studies were performed at our center between July 2004 and December 2009. We retrospectively reviewed the reports of patients to check rare sites of metastasis other than liver, bone, and lymph nodes. Lesions were confirmed on follow-up and/or other imaging methods (MRI, echocardiography, and ultrasound).
RESULTS: The different sites of metastasis according to frequency of occurrence were: cardiac (n = 29), breast (n = 21), retro-orbital (n = 9), uterus (n = 7), skin (n = 8), brain (n = 6), spleen (n = 3), testes (n = 1), seminal vesicle (n = 1), and intramuscular in psoas muscle (n = 4).
CONCLUSIONS: Cardiac and breast metastases appear to be not infrequent in neuroendocrine tumor patients. Ga-68 somatostatin-receptor PET/CT enables detection of these and other rare sites of metastasis.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 22918770     DOI: 10.1007/978-3-642-27994-2_20

Source DB:  PubMed          Journal:  Recent Results Cancer Res        ISSN: 0080-0015


  18 in total

1.  Demonstration of focal physiologic in-vivo somatostatin receptor expression in the caput epididymis of the testes on 68Ga-DOTANOC PET/CT and 177Lu-DOTATATE post-therapy whole body scintigraphy.

Authors:  Ashwin Singh Parihar; Apurva Sood; Ashwani Sood; Ajay Gulati; Bhagwant Rai Mittal
Journal:  Asia Ocean J Nucl Med Biol       Date:  2020

2.  Large cardiac metastasis from pancreatic neuroendocrine tumor and response to peptide receptor radionuclide therapy with 177Lu-DOTATATE.

Authors:  Rahul V Parghane; Sandip Basu
Journal:  J Nucl Cardiol       Date:  2018-08-27       Impact factor: 5.952

3.  Myocardial metastases from neuroendocrine tumors: incidence and relevance.

Authors:  Dik J Kwekkeboom
Journal:  Endocrine       Date:  2014-06-26       Impact factor: 3.633

Review 4.  Ileal neuroendocrine tumors and heart: not only valvular consequences.

Authors:  Jan Calissendorff; Eva Maret; Anders Sundin; Henrik Falhammar
Journal:  Endocrine       Date:  2014-10-16       Impact factor: 3.633

5.  Peptide receptor radionuclide therapy of treatment-refractory metastatic thyroid cancer using (90)Yttrium and (177)Lutetium labeled somatostatin analogs: toxicity, response and survival analysis.

Authors:  Hendra Budiawan; Ali Salavati; Harshad R Kulkarni; Richard P Baum
Journal:  Am J Nucl Med Mol Imaging       Date:  2013-12-15

6.  Rare case of concurrent suprasternal and cardiac metastasis from small bowel neuroendocrine tumour.

Authors:  Xinyi Nan; Anoj Dharmawardhane
Journal:  J Surg Case Rep       Date:  2022-06-22

7.  Metastases from neuroendocrine tumors to the breast are more common than previously thought. A diagnostic pitfall?

Authors:  Joakim Crona; Dan Granberg; Olov Norlén; Fredrik Wärnberg; Peter Stålberg; Per Hellman; Peyman Björklund
Journal:  World J Surg       Date:  2013-07       Impact factor: 3.352

8.  ⁶⁸Ga-DOTA-TOC-PET/CT detects heart metastases from ileal neuroendocrine tumors.

Authors:  Jan Calissendorff; Anders Sundin; Henrik Falhammar
Journal:  Endocrine       Date:  2013-11-23       Impact factor: 3.633

9.  Myocardial metastases on 6-[18F] fluoro-L-DOPA PET/CT: a retrospective analysis of 116 serotonin producing neuroendocrine tumour patients.

Authors:  Walter Noordzij; André P van Beek; René A Tio; Anouk N van der Horst-Schrivers; Elisabeth G de Vries; Bram van Ginkel; Annemiek M Walenkamp; Andor W Glaudemans; Riemer H Slart; Rudi A Dierckx
Journal:  PLoS One       Date:  2014-11-14       Impact factor: 3.240

10.  Pancreatic neuroendocrine tumor with metastasis to the spleen: a case report.

Authors:  Yasunaru Sakuma; Yoshikazu Yasuda; Naohiro Sata; Yoshinori Hosoya; Atsushi Shimizu; Hirofumi Fujii; Daisuke Matsubara; Noriyuki Fukushima; Atsushi Miki; Misato Maeno; Alan Kawarai Lefor
Journal:  BMC Cancer       Date:  2017-01-09       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.